Phosphodiesterase Inhibitors for Osteoarthritis Bone Edema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, such as pain relievers and NSAIDs, do not effectively address the underlying physiology causing pain, and surgical decompression for intraosseous hypertension is not ideal due to transient benefits and potential side effects.
Innovation Solution
Administering a therapeutically effective amount of a pharmaceutically acceptable bone edema medication, specifically vasoactive phosphodiesterase inhibitors like sildenafil, to reduce intraosseous hypertension by modulating blood flow and alleviating bone pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical decompression is used to treat intraosseous hypertension, then bone pain is relieved, but the benefit is transient and surgery produces side effects and complications
Solution Approach 1:
The patent replaces the mechanical surgical intervention (decompressive surgery) with a pharmacological system (phosphodiesterase inhibitors). The medication modulates blood flow to bone through biochemical mechanisms, eliminating the need for surgical incisions, fenestrations, and associated surgical risks while achieving sustained reduction of intraosseous hypertension and bone pain.
Solution Approach 2:
The patent changes the physiological parameters of blood flow to bone by administering phosphodiesterase inhibitors. These medications alter vascular tone and blood flow dynamics, reducing intraosseous pressure and edema without mechanical intervention. This parameter-based approach provides sustained effect without the transient nature of surgical decompression.
2Ease of operation
If pain relievers or NSAIDs are administered, then pain is blocked or inflammation is reduced, but the underlying physiology producing pain is not affected
Solution Approach 1:
The patent converts the harmful accumulation of edema fluid and elevated intraosseous pressure (which causes pain) into a target for therapeutic intervention. By using phosphodiesterase inhibitors to specifically reduce bone edema and intraosseous hypertension, the treatment addresses the root cause of pain rather than merely masking symptoms, thereby providing both relief and disease modification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces or eliminates intraosseous hypertension, thereby alleviating joint pain associated with osteoarthritis, providing a safer and more sustainable pain relief compared to surgical decompression.
Implementation Method 1
phosphodiesterase inhibitors, which modulate blood flow to bone of a patient in the vicinity of an arthritic joint
Implementation Method 2
vasoactive medications, such as phosphodiesterase inhibitors, which modulate blood flow to bone
Implementation Method 3
altering vascular profusion (blood flow in and out of the bone), thereby reducing bone edema
Implementation Method 4
reduce or eliminate intraosseous hypertension in the bone, within the vicinity of the affected joint, by altering vascular profusion
Data Source
AI summary
A method of treating osteoarthritis by reducing intraosseous hypertension in a patient in need thereof by administering to a patient an effective amount of a composition containing a bone edema medication, such as a vasoactive medication or phosphodiesterase inhibitor, including a PDE-5.